Compare Cadila Healthcare with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PANACEA BIOTECH - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PANACEA BIOTECH CADILA HEALTHCARE/
PANACEA BIOTECH
 
P/E (TTM) x 35.2 17.0 207.3% View Chart
P/BV x 6.2 6.6 93.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 CADILA HEALTHCARE   PANACEA BIOTECH
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
PANACEA BIOTECH
Mar-19
CADILA HEALTHCARE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs352354 99.6%   
Low Rs207138 149.4%   
Sales per share (Unadj.) Rs139.274.6 186.7%  
Earnings per share (Unadj.) Rs11.86.7 176.1%  
Cash flow per share (Unadj.) Rs18.615.5 119.8%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs101.457.2 177.2%  
Shares outstanding (eoy) m1,023.7461.25 1,671.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.03.3 60.9%   
Avg P/E ratio x23.736.8 64.5%  
P/CF ratio (eoy) x15.015.9 94.8%  
Price / Book Value ratio x2.84.3 64.1%  
Dividend payout %29.80-   
Avg Mkt Cap Rs m286,03315,061 1,899.1%   
No. of employees `00013.42.3 579.3%   
Total wages/salary Rs m24,1451,471 1,641.6%   
Avg. sales/employee Rs Th10,632.71,973.6 538.7%   
Avg. wages/employee Rs Th1,801.2635.6 283.4%   
Avg. net profit/employee Rs Th898.5176.8 508.2%   
INCOME DATA
Net Sales Rs m142,5314,567 3,120.9%  
Other income Rs m1,13945 2,542.4%   
Total revenues Rs m143,6704,612 3,115.3%   
Gross profit Rs m24,1982,030 1,192.2%  
Depreciation Rs m6,965540 1,289.8%   
Interest Rs m3,4181,048 326.1%   
Profit before tax Rs m14,954486 3,075.7%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,19877 4,147.9%   
Profit after tax Rs m12,044409 2,944.0%  
Gross profit margin %17.044.4 38.2%  
Effective tax rate %21.415.9 134.9%   
Net profit margin %8.59.0 94.3%  
BALANCE SHEET DATA
Current assets Rs m87,1542,415 3,609.6%   
Current liabilities Rs m82,6949,077 911.0%   
Net working cap to sales %3.1-145.9 -2.1%  
Current ratio x1.10.3 396.2%  
Inventory Days Days7165 109.7%  
Debtors Days Days9471 132.3%  
Net fixed assets Rs m133,2368,333 1,598.8%   
Share capital Rs m1,02461 1,670.5%   
"Free" reserves Rs m102,7333,443 2,984.1%   
Net worth Rs m103,7573,504 2,961.1%   
Long term debt Rs m32,146461 6,970.1%   
Total assets Rs m236,86613,755 1,722.0%  
Interest coverage x5.41.5 367.2%   
Debt to equity ratio x0.30.1 235.4%  
Sales to assets ratio x0.60.3 181.2%   
Return on assets %6.510.6 61.6%  
Return on equity %11.611.7 99.4%  
Return on capital %13.738.7 35.5%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m52,7521,203 4,384.9%   
Fx outflow Rs m14,504467 3,108.0%   
Net fx Rs m38,248736 5,194.1%   
CASH FLOW
From Operations Rs m25,0541,049 2,388.8%  
From Investments Rs m-10,123-54 18,921.5%  
From Financial Activity Rs m-10,942-1,011 1,081.9%  
Net Cashflow Rs m3,989-20 -20,248.7%  

Share Holding

Indian Promoters % 74.8 74.5 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.6 1,383.3%  
FIIs % 5.9 1.3 453.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 23.6 46.6%  
Shareholders   44,069 10,259 429.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   JUBILANT PHARMOVA   DR. DATSONS LABS  FDC  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Asian Paints Rallies 7% Post Q4 Results(09:30 am)

Asian stock markets climbed today after US benchmarks halted a three-day slide, with signs of a strengthening labor market outweighing investors' concerns about rising inflation.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 14, 2021 11:37 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS